Fate Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies aimed at addressing cancer and autoimmune diseases. Utilizing a proprietary iPSC product platform, Fate Therapeutics is recognized for its advanced capabilities in creating multiplexed-engineered iPSC lines and manufacturing off-the-shelf, iPSC-derived cell products. Their pipeline includes innovative therapies featuring engineered natural killer (NK) cells and T-cells that deploy synthetic controls for enhanced targeting of tumor-associated antigens. The company's commitment to scientific excellence seeks to transform patient care and improve outcomes through innovative cell therapy solutions. Headquartered in San Diego, CA, Fate Therapeutics values diversity and fosters an inclusive workplace, adhering to principles of integrity and collaboration as part of its organizational culture.